Petrov Institute:
Working together to lead personalised cancer research in Russia

This video features the N.N. Petrov Institute for Oncology, one of Russia’s leading cancer research institutions. Together, we are working to identify innovative new approaches to treating cancer.

More info and download available here


LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

Nobel_Prize_II_THM 20 October 2014

Stimulating the next generation: the Nobel Prize Inspiration Initiative

A_neuroscience_vision_THM 16 October 2014

A Neuroscience Vision: Right Partner, Right Time, Right Place

Biomedical_innovation_THM 19 September 2014

Biomedical innovation in emerging markets – understanding the strengths and weaknesses of individual markets

Latest press releases

Lynparza™ (olaparib) receives positive CHMP opinion in the EU for the maintenance treatment of BRCA-mutated platinum sensitive relapsed ovarian cancer
24 October 2014
AstraZeneca strengthens partnership with the University of Cambridge
16 October 2014
Positive results from Phase IIb benralizumab study in severe asthma published in The Lancet Respiratory Medicine
9 October 2014
AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress
27 September 2014
MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation
26 September 2014
IRESSA receives CHMP positive opinion to include blood based diagnostic testing in European label
26 September 2014
MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory to develop new biologic cancer medicines
25 September 2014
Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes
19 September 2014
FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain
16 September 2014
AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease
16 September 2014
AstraZeneca to present research from its innovative diabetes portfolio at the 2014 Meeting of the European Association for the Study of Diabetes
10 September 2014
Benralizumab Phase II COPD study published in The Lancet Respiratory Medicine
8 September 2014